IL6 and neoplasm: Inhibition of IL-6R, PD-L1 or EGFR resulted in CXCL7 decline (Figure 6E, 6K-M), and shCXCL7 decreased MCT-1, IL-6/IL-6R, p-EGFR and PD-L1 (Figure 6J), which may potentiate therapeutic efficacy against tumor spreading via lymphatic circulation.